Please login to the form below

Not currently logged in
Email:
Password:

Emflaza

This page shows the latest Emflaza news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer unimpressed with PTC’s Translarna

FDA reviewer unimpressed with PTC’s Translarna

saying its commercial operations were already in gear following the FDA’s approval of Emflaza (deflazacort) for DMD earlier this year.

Latest news

  • Connecting the dots Connecting the dots

    Not just any drug mind you - a decades-old corticosterioid called Emflaza (deflazacort) that is available elsewhere for about $1, 500 per year.

  • Marathon pauses Emflaza launch amid pricing furore Marathon pauses Emflaza launch amid pricing furore

    Marathon pauses Emflaza launch amid pricing furore. US Senator Bernie Sanders calls Duchenne muscular dystrophy drug’ s pricing “ unconscionable”. ... In response, Marathon has said it is "pausing its commercialisation plans" for Emflaza while it

  • FDA approves first steroid for Duchenne muscular dystrophy FDA approves first steroid for Duchenne muscular dystrophy

    Emflaza (deflazacort) is the first corticosteroid to be approved by the FDA to treat DMD, said the US agency in a statement. ... Marathon insists that Emflaza causes fewer side effects than prednisone and so warrants premium pricing.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics